Argus Research Raises Merck Price Target to $170 as Stock Nears 52-Week High

By TrendSpider Editor

Argus Research analyst Jasper Hellweg reaffirmed a buy rating on Merck and Company, Inc. while lifting the price target from $145 to $170, implying meaningful upside from the current price of $153.73. The confirmation arrives as MRK trades near the top of its 52-week range of $77.58 to $154.49, just

Argus Research Raises Merck Price Target to $170 as Stock Nears 52-Week High

Argus Research analyst Jasper Hellweg reaffirmed a buy rating on Merck and Company, Inc. while lifting the price target from $145 to $170, implying meaningful upside from the current price of $153.73. The confirmation arrives as MRK trades near the top of its 52-week range of $77.58 to $154.49, just cents below the annual peak. Shares gained 2.02% in Tuesday's session, signaling that the market is responding constructively to the renewed institutional conviction.

Key Drivers of the MRK Stock Move

• Main Catalyst: Argus Research analyst Jasper Hellweg confirmed a buy rating on MRK and raised the price target to $170 from a prior target of $145, a $25 increase that reflects a materially more constructive longer-term view on the stock.
• Bull Case: The revised price target of $170 sits roughly 10.6% above the current price of $153.73 and exceeds the existing 52-week high of $154.49, suggesting Argus sees the stock breaking into new all-time high territory. The 2.02% single-session gain reinforces that the upgrade is attracting real buying interest.
• Bear Case: At $153.73, MRK is trading within cents of its 52-week high of $154.49, leaving limited technical cushion before the stock enters potentially extended territory. Investors buying near the top of a multi-month range face elevated risk of a mean reversion pullback, particularly if broader market conditions shift before Merck can validate the higher price target through fundamentals.

The timing of Argus Research's price target hike is notable given how compressed the gap has become between the current price and the 52-week ceiling. Hellweg's decision to raise the target from $145 to $170 rather than make a marginal adjustment signals a conviction-level reassessment of Merck's forward earnings or pipeline value. The average price target now stands at $170, which aligns with the Argus call and represents a clean setup for further institutional accumulation if MRK can break and hold above $154.49. Traders will be watching closely to see whether Tuesday's momentum carries the stock through that technical ceiling in the sessions ahead, or whether supply at the prior high creates a consolidation before any sustained move higher.

MRK Analyst Ratings and Price Targets

Argus Research analyst Jasper Hellweg confirmed a buy rating on Merck on August 25, 2026, raising the price target to $170 from a prior target of $145. This is the sole analyst action in the current data set. The average price target across tracked analyst estimates stands at $170, consistent with the Argus call.

MRK Seasonality

Late August has historically been a mixed period for large-cap pharmaceutical stocks, as end-of-summer trading volume tends to thin out ahead of the September catalyst season, which often includes medical conferences and pipeline data readouts. A confirmed buy rating entering this window can carry extra weight if it draws institutional positioning ahead of any fall announcements from Merck.

MRK Relative Performance

MRK's 2.02% gain on Tuesday puts it in notably stronger shape than a typical session for large-cap healthcare peers, many of which trade with lower daily volatility given their defensive characteristics. Trading at $153.73 against a 52-week low of $77.58, the stock has nearly doubled from its annual bottom, outpacing the broader healthcare sector's generally more modest recovery arc over the same period. The proximity to the $154.49 high suggests Merck has been one of the standout performers in its peer group over the trailing year.